A Phase IIIA, Blinded, Randomized, Controlled. Multinational, Consistency Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' MMR Vaccine,(209762) Compared to Merck & Co., Inc.'s MMR Vaccine as a First

Project Details

StatusFinished
Effective start/end date8/10/1331/10/18

Funding

  • GlaxoSmithKline: $50,883.00

Keywords

  • Biotechnology & Drug Development, Infectious Diseases